Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
These 3 Dividend Stocks Yield More Than 5% but Their Payout Ratios Are Over 100%. Are Dividend Cuts Coming?
Relying on payout ratio alone can sometimes give investors a misleading picture of just how safe a dividend payment is. 
Via The Motley Fool
3 Cheap Dividend Stocks to Snatch Up Now
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors. 
Via InvestorPlace
Get Rich Quick with These 7 Growth Stocks to Buy Now
Here are seven growth stocks to buy that will let you know by their price action if the current bull market is ready to expand. 
Via InvestorPlace
Wall Street Favorites: 7 Long-Term Stocks With Strong Buy Ratings for February 2024
The stock market is soaring, and many analysts are worried about a bubble. Still, these seven long-term stocks are still great buys today. 
Via InvestorPlace
Exploring NYSE:PFE's dividend characteristics.
Exploring PFIZER INC (NYSE:PFE)'s dividend characteristics. 
Via Chartmill
2 Ultra-High-Yield Dividend Stocks Billionaires Can't Stop Buying, and 1 They Can't Sell Fast Enough
Two brand-name income stocks with yields north of 6% were gobbled up by prominent billionaires in the December-ended quarter, while a dividend stock with a 15% yield found itself on the chopping... 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
7 Blue-Chip Stocks to Pick Up While They’re Down
Build a robust investment portfolio and make the most of the discount with these blue-chip stocks to buy and hold. 
Via InvestorPlace
ROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - February 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Patience will be rewarded with these stocks. 
Via The Motley Fool
MarketBeat Week in Review – 2/12 - 2/16
Higher inflation readings dampened expectations for rate cuts, and a shortened trading week may get more volatile when many retail stocks report earnings 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Pfizer's Expansion Sparks Boom for these Healthcare REITs
Via Benzinga
7 F-Rated Stocks to Sell for February 2024
The stock market is off to a good start and there are plenty of great names out there. So don't hold on to your F-rated stocks to sell. 
Via InvestorPlace
Pfizer's Mixed Bag: A Look At The Fourth Quarter 2023 Earnings Call - Main Takeaways
Pfizer Inc. (NYSE: PFE) recently held its fourth-quarter earnings call, revealing a year of contrasts for the pharmaceutical giant. While the company faced setbacks, particularly with its COVID-19... 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
From Pfizer Inc.
Via Business Wire
The 7 Best Dividend Stocks to Buy in February 2024
The market is soaring and many sectors appear overvalued. Fortunately, these leading dividend stocks are still available at great prices. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Pfizer at 10-year support: Is it a massive buy opportunity?
As Pfizer's stock nears 10-year support at $26, with better-than-expected earnings despite declining COVID-19-related revenue, is now the time to buy? 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
7 Undervalued Dividend Stocks to Buy in February for High Total Returns
The undervalued dividend stocks could see serious growth before too long. Plus, they pay you to hold them while you wait. 
Via InvestorPlace
Pfizer Agrees To Pay $93M To Settle Lipitor Antitrust Lawsuit Despite Calling Allegations 'Factually And Legally Without Merit'
Pfizer has agreed to pay $93 million to settle an antitrust lawsuit related to its cholesterol drug Lipitor. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Biden Boom: 7 Stocks to Buy if Democrats Win the Election in 2024
Election-proof your portfolio: these seven stocks could deliver significant gains if Biden wins the election in 2024. 
Via InvestorPlace
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.